Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC

NEW BRUNSWICK, N.J., December 16, 2021 - Remarks made by Penny Heaton, Global R&D Head of Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson:Good afternoon. My name is Penny Heaton, and I am the Global R&D Head for Vaccines at Janssen.Let me state at the outset that based on data, we are confident in the positive benefit-risk profile of our vaccine. It is saving lives here in the US today and on every continent around the globe. Our vaccine is different. It is long-lasting, it offers high levels of protection, and it provides breadth of protection. Our vaccine has flexible dosing, is easy to store and transport. In many low- and middle-income countries our vaccine is the most important and sometimes only option. Even in the U.S, given its durability, it may be the preferred choice for people who can’t or won’t return for multiple vaccinations. The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority. We strongly support education and awareness of rare events such as Thrombosis with Thrombocytopenia Syndrome—or TTS. We also have several studies underway to help us identify factors that may be associated with the development of TTS and the mechanism by which it occurs. Although rare, we recognize that the incidence of TTS associated with the Johnson & Johnson vaccine is highest in women aged 30 to 49 years and can be fatal if not treated. TTS continues to be a rare event, but, unfortu...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news